Severe short-term adverse events in related bone marrow or peripheral blood stem cell donors.
BM collection
Donor safety
Family donors
PBSC harvest
Poor mobilizer
Related donation
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
12
08
2022
accepted:
06
11
2022
revised:
02
11
2022
pubmed:
21
11
2022
medline:
3
3
2023
entrez:
20
11
2022
Statut:
ppublish
Résumé
The incidence of severe adverse events (SAEs) and associated risk factors in hematopoietic cell transplantation donors needs to be clarified for related donors (relatives of the transplant recipient), whose criteria for donation are more lenient than for unrelated donors. Data from related donors registered in the Japanese national data registry database between 2005 and 2021 were evaluated to determine the association of short-term SAE incidence with donor characteristics at registration.Fourteen of 4339 bone marrow (BM) donors (0.32%) and 54 of 10,684 peripheral blood stem cell (PBSC) donors (0.51%) experienced confirmed SAEs during the short donation period. No deaths were observed. Past medical history was a common risk factor for SAEs in both BM and PBSC donors. Age of 60 years or older and female sex were identified as risk factors for SAEs in PBSC donors. Female sex was also a risk factor for poor mobilization, which resulted in discontinuation of PBSC collection.Although donors should be selected carefully, a certain level of safety is ensured for related donors in Japan. Donor safety should be further increased by improving the selection method for related donors and extending the follow-up period.
Identifiants
pubmed: 36403180
doi: 10.1007/s12185-022-03489-4
pii: 10.1007/s12185-022-03489-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
421-427Informations de copyright
© 2022. Japanese Society of Hematology.
Références
Anderlini P, Korbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D, et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood. 1997;90:903–8.
pubmed: 9242518
Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G, et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica. 2009;94:94–101.
doi: 10.3324/haematol.13668
pubmed: 19059940
Horowitz MM, Confer DL. Evaluation of hematopoietic stem cell donors. Hematol Am Soc Hematol Educ Progr. 2005;2005:469–75.
doi: 10.1182/asheducation-2005.1.469
Halter JP, van Walraven SM, Worel N, Bengtsson M, Hagglund H, Nicoloso de Faveri G, et al. Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Bone Marrow Transpl. 2013;48:220–5.
doi: 10.1038/bmt.2012.119
Shaw BE, Ball L, Beksac M, Bengtsson M, Confer D, Diler S, et al. Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations. Bone Marrow Transpl. 2010;45:832–8.
doi: 10.1038/bmt.2010.2
Holig K, Kramer M, Kroschinsky F, Bornhauser M, Mengling T, Schmidt AH, et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood. 2009;114:3757–63.
doi: 10.1182/blood-2009-04-218651
pubmed: 19666868
Anthias C, Shaw BE, Kiefer DM, Liesveld JL, Yared J, Kamble RT, et al. Significant improvements in the practice patterns of adult related donor care in US transplantation centers. Biol Blood Marrow Transpl. 2016;22:520–7.
doi: 10.1016/j.bbmt.2015.11.008
Clare S, Mank A, Stone R, Davies M, Potting C, Apperley JF, et al. Management of related donor care: a European survey. Bone Marrow Transpl. 2010;45:97–101.
doi: 10.1038/bmt.2009.117
O’Donnell PV, Pedersen TL, Confer DL, Rizzo JD, Pulsipher MA, Stroncek D, et al. Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States. Blood. 2010;115:5097–101.
doi: 10.1182/blood-2010-01-262915
pubmed: 20228276
pmcid: 2890146
Kodera Y, Yamamoto K, Harada M, Morishima Y, Dohy H, Asano S, et al. PBSC collection from family donors in Japan: a prospective survey. Bone Marrow Transpl. 2014;49:195–200.
doi: 10.1038/bmt.2013.147
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transpl. 2013;48:452–8.
doi: 10.1038/bmt.2012.244
Ruesch M, Amar El Dusouqui S, Buhrfeind E, Buser A, Chalandon Y, Frey BM, et al. Basic characteristics and safety of donation in related and unrelated haematopoietic progenitor cell donors - first 10 years of prospective donor follow-up of Swiss donors. Bone Marrow Transpl. 2022;57:918–24.
doi: 10.1038/s41409-022-01656-z
Anthias C, Ethell ME, Potter MN, Madrigal A, Shaw BE. The impact of improved JACIE standards on the care of related BM and PBSC donors. Bone Marrow Transpl. 2015;50:244–7.
doi: 10.1038/bmt.2014.260
Switzer GE, Bruce J, Kiefer DM, Kobusingye H, Drexler R, Besser RM, et al. Health-related quality of life among older related hematopoietic stem cell donors (>60 Years) is equivalent to that of younger related donors (18 to 60 Years): a related donor safety study. Biol Blood Marrow Transpl. 2017;23:165–71.
doi: 10.1016/j.bbmt.2016.10.008
Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, et al. Effect of aging and predonation comorbidities on the related peripheral blood stem cell donor experience: report from the related donor safety study. Biol Blood Marrow Transpl. 2019;25:699–711.
doi: 10.1016/j.bbmt.2018.11.004
Lysak D, Koristek Z, Gasova Z, Skoumalova I, Jindra P. Efficacy and safety of peripheral blood stem cell collection in elderly donors; does age interfere? J Clin Apher. 2011;26:9–16.
doi: 10.1002/jca.20269
pubmed: 21312254
Murata M, Harada M, Kato S, Takahashi S, Ogawa H, Okamoto S, et al. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors. Bone Marrow Transpl. 1999;24:1065–71.
doi: 10.1038/sj.bmt.1702038
Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch DC, Watts MJ. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol. 2006;134:517–25.
doi: 10.1111/j.1365-2141.2006.06223.x
pubmed: 17018030
Bailen R, Perez-Corral AM, Pascual C, Kwon M, Serrano D, Gayoso J, et al. Factors predicting peripheral blood progenitor cell mobilization in healthy donors in the era of related alternative donors: Experience from a single center. J Clin Apher. 2019;34:373–80.
doi: 10.1002/jca.21685
pubmed: 30694583
Suzuya H, Watanabe T, Nakagawa R, Watanabe H, Okamoto Y, Onishi T, et al. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang. 2005;89:229–35.
doi: 10.1111/j.1423-0410.2005.00701.x
pubmed: 16262756
Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, et al. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. Haematologica. 2019;104:844–54.
doi: 10.3324/haematol.2018.200121
pubmed: 30381298
pmcid: 6442962
Farhadfar N, Ahn KW, Bo-Subait S, Logan B, Stefanski HE, Hsu JW, et al. The impact of pre-apheresis health related quality of life on peripheral blood progenitor cell yield and donor’s health and outcome: secondary analysis of patient-reported outcome data from the rdsafe and bmt ctn 0201 clinical trials. Transpl Cell Ther. 2022;28(603):e1–7.